Wolfe Research downgraded Bruker to Peer Perform from Outperform without a price target. The firm reduced 2025 and 2026 earnings estimates given continued concerns about the pace of improvement in instrument demand and the long-lead times for Bruker’s major instruments. Wolfe also has continued concerns about the outlook for a China rebound. Given the likelihood of near-term downward earnings revisions and uncertainties, Bruker’s risk/reward is balanced, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz
- Illumina upgraded, Fiserv initiated: Wall Street’s top analyst calls
- Wells Fargo starts tools and diagnostics group with positive bias
- Bruker initiated with an Overweight at Wells Fargo
- Dr. Philip Ma Resigns from Bruker Board of Directors